Halozyme Therapeutics | HALO - Credores Comerciais

Preço das Ações
63.70
Mudança Diária
0.64 1.01%
Mensal
-1.44%
Anual
6.11%
Q2 Previsão
63.96




Credores Comerciais Alterar Data
Acadia Pharmaceuticals USD 10.9M 10.84M 2025-12
Agios Pharmaceuticals USD 13.75M 4.61M 2026-03
Alnylam Pharmaceuticals USD 126.63M 10.91M 2026-03
Amarin USD 48.15M 2.8M 2026-03
Amgen USD 20.89B 1.25B 2025-12
Baxter International USD 999M 46M 2025-12
Cara Therapeutics USD 4.08M 1.65M 2025-09
Cytokinetics USD 105.62M 83.53M 2025-12
DBV Technologies USD 39.82M 972K 2025-09
Eli Lilly USD 5.03B 350M 2026-03
Esperion Therapeutics USD 65.07M 12.44M 2025-12
Halozyme Therapeutics USD 20.9M 5.54M 2025-12
Intrexon USD 4.85M 3.12M 2024-06
Ionis Pharmaceuticals USD 26.03M 2.05M 2026-03
MannKind USD 9.03M 1.76M 2025-12
Minerva Neurosciences USD 640K 305K 2025-12
Nektar Therapeutics USD 10.77M 4.79M 2025-12
Pfizer USD 5.02B 142M 2025-09
Rigel Pharmaceuticals USD 3.85M 3.44M 2025-09
United Therapeutics USD 7.1M 460.9M 2025-12
Vanda Pharmaceuticals USD 39.09M 33.28M 2024-12